Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David M. Peereboom, Louis B. Nabors, Priya Kumthekar, Michael A. Badruddoja, Karen L. Fink, Frank S. Lieberman, Surasak Phuphanich, Erin M. Dunbar, Tobias Walbert, David Schiff, David Dinh Tran, Lynn Stuart Ashby, Nicholas A. Butowski, Fabio Massaiti Iwamoto, Ross Lindsay, John Bullington, Michael Schulder, Jonathan Sherman, Trishna Goswami, David A. Reardon
Institutions: Cleveland Clinic, University of Alabama at Birmingham, Northwestern Memorial Hospital, Community Health Systems - Northwest Medical Center, University of Pittsburgh, Cedars-Sinai Medical Center, Piedmont Atlanta Hospital, Henry Ford Hospital, University of Virginia Health System, Washington University in St. Louis, Barrow Neurological Institute, University of California, San Francisco, Columbia University Irving Medical Center, Stemline Therapeutics (United States), Northwell Health, George Washington University, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890836303